Hepatitis

A team of researchers, backed by a grant totaling more than $3 million, will study the feasibility of a nationwide opt-out testing program to detect…

In ongoing proof-of-concept Phase 2a trials, Arbutus BioPharma’s imdusiran is showing an ability to possibly eliminate chronic hepatitis B infections when used in…

Bluejay Therapeutics’ investigational antibody therapy BJT-778 appears to safely and effectively lower levels of the hepatitis D virus (HDV) and markers of liver inflammation…

Vir Biotechnology’s investigational therapy tobevibart, used alone or in combination with another company candidate called elebsiran, can reduce hepatitis D virus (HDV) levels and…

A test-and-treat strategy was effective at identifying and treating hepatitis C among migrants and refugees in Italy coming from low-income countries where the condition…

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to larsucosterol, Durect’s investigational therapy for people with severe alcohol-associated hepatitis…

A Phase 2a clinical trial testing Kezar Life Sciences’ investigational therapy zetomipzomib in adults with autoimmune hepatitis who did not respond well to standard…

Global rates for evaluating chronic hepatitis B and starting appropriate treatment are lower than they should be, especially among women and Asian minorities living…

Throughout May, the U.S. Centers for Disease Control and Prevention (CDC) will work with public health partners to raise awareness of viral hepatitis…

Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts will help the World Health…